ATE538808T1 - Kombinierte dns/protein impfstoffzusammensetzungen - Google Patents

Kombinierte dns/protein impfstoffzusammensetzungen

Info

Publication number: ATE538808T1
Authority: AT; Austria
Prior art keywords: dna; combined dna; vaccine compositions; protein vaccine; combined
Prior art date: 2002-03-28

Application number

AT03720397T

Other languages

English (en)

Inventor

Hansjoerg Reimann

Reinhold Schirmbeck

Erik Lindblad

Original Assignee

Brenntag Biosector As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-28

Filing date

2003-03-28

Publication date

2012-01-15

2003-03-28 Application filed by Brenntag Biosector As filed Critical Brenntag Biosector As

2012-01-15 Application granted granted Critical

2012-01-15 Publication of ATE538808T1 publication Critical patent/ATE538808T1/de

Links

239000000203 mixture Substances 0.000 title abstract 2
229940023143 protein vaccine Drugs 0.000 title abstract 2
108010041986 DNA Vaccines Proteins 0.000 abstract 3
229940021995 DNA vaccine Drugs 0.000 abstract 3
239000002671 adjuvant Substances 0.000 abstract 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 abstract 1
229910052782 aluminium Inorganic materials 0.000 abstract 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
159000000007 calcium salts Chemical class 0.000 abstract 1
230000002708 enhancing effect Effects 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
230000005847 immunogenicity Effects 0.000 abstract 1
229910052500 inorganic mineral Inorganic materials 0.000 abstract 1
239000011707 mineral Substances 0.000 abstract 1
102000039446 nucleic acids Human genes 0.000 abstract 1
108020004707 nucleic acids Proteins 0.000 abstract 1
150000007523 nucleic acids Chemical class 0.000 abstract 1
239000013612 plasmid Substances 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Communicable Diseases (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT03720397T 2002-03-28 2003-03-28 Kombinierte dns/protein impfstoffzusammensetzungen ATE538808T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02076276		2002-03-28
EP03075383		2003-02-10
PCT/EP2003/003353 WO2003082327A2 (en)	2002-03-28	2003-03-28	Combined dna/protein vaccine compositions

Publications (1)

Publication Number	Publication Date
ATE538808T1 true ATE538808T1 (de)	2012-01-15

Family

ID=28676388

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03720397T ATE538808T1 (de)	2002-03-28	2003-03-28	Kombinierte dns/protein impfstoffzusammensetzungen

Country Status (9)

Country	Link
US (1)	US20050129712A1 (de)
EP (1)	EP1490100B1 (de)
AT (1)	ATE538808T1 (de)
AU (1)	AU2003224017A1 (de)
CA (1)	CA2480690A1 (de)
DK (1)	DK1490100T3 (de)
ES (1)	ES2379346T3 (de)
IL (1)	IL164256A0 (de)
WO (1)	WO2003082327A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9238679B2 (en)	2011-02-11	2016-01-19	The Trustees Of The University Of Pennslyvania	Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
EA037377B1 (ru)	2011-02-11	2021-03-22	Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания	Вакцина для индукции иммунного ответа на hbv
CN111388662B (zh) *	2020-03-12	2023-03-10	潍坊华英生物科技有限公司	一种小鹅瘟病毒的复合疫苗及卵黄抗体制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69319728T2 (de) *	1992-05-23	1999-02-04	Smithkline Beecham Biologicals S.A., Rixensart	Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
CA2244110A1 (en) *	1996-02-12	1997-08-14	Cobra Therapeutics Limited	Novel methods of vaccination and vaccines thereof comprising a nucleic acid encoding a first epitope and a peptide containing a second epitope
GB9726555D0 (en) *	1997-12-16	1998-02-11	Smithkline Beecham Plc	Vaccine
JP2002520299A (ja) *	1998-07-09	2002-07-09	メルクエンドカムパニーインコーポレーテッド	ポリヌクレオチドワクチン配合物
GB9910375D0 (en) *	1999-05-05	1999-06-30	Lindahl Gunnar	Vaccine composition

2003
- 2003-03-28 WO PCT/EP2003/003353 patent/WO2003082327A2/en not_active Ceased
- 2003-03-28 US US10/509,498 patent/US20050129712A1/en not_active Abandoned
- 2003-03-28 DK DK03720397.3T patent/DK1490100T3/da active
- 2003-03-28 IL IL16425603A patent/IL164256A0/xx unknown
- 2003-03-28 CA CA002480690A patent/CA2480690A1/en not_active Abandoned
- 2003-03-28 ES ES03720397T patent/ES2379346T3/es not_active Expired - Lifetime
- 2003-03-28 AT AT03720397T patent/ATE538808T1/de active
- 2003-03-28 AU AU2003224017A patent/AU2003224017A1/en not_active Abandoned
- 2003-03-28 EP EP03720397A patent/EP1490100B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DK1490100T3 (da)	2012-03-12
ES2379346T3 (es)	2012-04-25
CA2480690A1 (en)	2003-10-09
US20050129712A1 (en)	2005-06-16
WO2003082327A2 (en)	2003-10-09
WO2003082327A3 (en)	2004-03-04
AU2003224017A1 (en)	2003-10-13
EP1490100A2 (de)	2004-12-29
IL164256A0 (en)	2005-12-18
EP1490100B1 (de)	2011-12-28

Publication	Publication Date	Title
EP3294326B1 (de)	2021-04-21	Prime-boost-schemata mit verabreichung von mindestens einem mrna-konstrukt
DE60039198D1 (de)	2008-07-24	Adjuvanszusammensetzungen zur Erhöhung der Immunantwort bezüglich Polynukleotid-basierenden Impfstoffen
IL150602A0 (en)	2003-02-12	Proteosome influenza vaccine
PT1487485E (pt)	2011-03-11	Adjuvantes de imidazoquinolina para vacinas de adn
CY1112749T1 (el)	2016-02-10	Εμβολια διεγερσης/αναμνησης κατα της ελονοσιας
DE60239594D1 (de)	2011-05-12	Influenza vakzinzusammensetzungen zur intradermaler verabreichung
BRPI0607840A2 (pt)	2009-06-13	uso de uma composição imunogência, e de um antìgeno de vzv, vacina ou composição imunogênica, e, kit
IL187616A (en)	2014-02-27	Use of an adjuvant compound containing polyinosinic acid – polycytidylic acid, antibiotics, and positive ion as an immunosuppressant
AR014182A1 (es)	2001-02-07	Composiciones de vacunas utiles para el tratamiento o profilaxis de tumores o lesiones inducidas por hpv; procedimiento para prevenir o tratar tumoresinducidos por hpv y procedimiento para preparar dichas composiciones
RU2009144125A (ru)	2011-07-27	Виросомы, содержащие гемагглютинин, полученный из вируса гриппа, вырабатываемого в клеточной линии; композиции, методы получения и применение на их основе
GB2386072A (en)	2003-09-10	Novel vaccine
ATE284613T1 (de)	2005-01-15	Polynukleotid-impfstoff-formulierungen
WO2006136460A8 (en)	2007-04-19	New adjuvant
IL164256A0 (en)	2005-12-18	Combined dna/protein compositions
CO5300406A1 (es)	2003-07-31	Vacuna
ATE420658T1 (de)	2009-01-15	Imidazoquinolinamine als adjuvantien für hiv dna vakzine
WO2001070265A3 (en)	2002-07-04	Lipopeptide adjuvants
DK1227840T3 (da)	2008-02-04	Adjuverede, genetiske vacciner
DE602005021873D1 (de)	2010-07-29	Neues impfstoffadjuvans und dessen herstellung und verwendung
DE69942161D1 (de)	2010-04-29	Genetische Adjuvanz-Impfstoffe
WO2005030802A3 (en)	2005-09-09	Antigens for an east coast fever vaccine